About: Treatable traits and therapeutic targets: Goals for systems biology in infectious disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatable traits and therapeutic targets: Goals for systems biology in infectious disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatable traits and therapeutic targets: Goals for systems biology in infectious disease
Creator	Kenneth Baillie, J Russell, Clark
Source	Elsevier; Medline; PMC
abstract	Among the many medical applications of systems biology, we contend that infectious disease is one of the most important and tractable targets. We take the view that the complexity of the immune system is an inevitable consequence of its evolution, and this complexity has frustrated reductionist efforts to develop host-directed therapies for infection. However, since hosts vary widely in susceptibility and tolerance to infection, host-directed therapies are likely to be effective, by altering the biology of a susceptible host to induce a response more similar to a host who survives. Such therapies should exert minimal selection pressure on organisms, thus greatly decreasing the probability of pathogen resistance developing. A systems medicine approach to infection has the potential to provide new solutions to old problems: to identify host traits that are potentially amenable to therapeutic intervention, and the host immune factors that could be targeted by host-directed therapies. Furthermore, undiscovered sub-groups with different responses to treatment are almost certain to exist among patients presenting with life-threatening infection, since this population is markedly clinically heterogeneous. A major driving force behind high-throughput clinical phenotyping studies is the aspiration that these subgroups, hitherto opaque to observation, may be observed in the data generated by new technologies. Subgroups of patients are unlikely to be static – serial clinical and biological phenotyping may reveal different trajectories through the pathophysiology of disease, in which different therapeutic approaches are required. We suggest there are two major goals for systems biology in infection medicine: (1) to identify subgroups of patients that share treatable features; and, (2) to integrate high-throughput data from clinical and in vitro sources in order to predict tractable therapeutic targets with the potential to alter disease trajectories for individual patients.
has issue date	2017-04-27(xsd:dateTime)
bibo:doi	10.1016/j.coisb.2017.04.003
bibo:pmid	32363252
has license	no-cc
sha1sum (hex)	c805511b956fda272fe0b6a09c9e000bc661bfaf
schema:url	https://doi.org/10.1016/j.coisb.2017.04.003
resource representing a document's title	Treatable traits and therapeutic targets: Goals for systems biology in infectious disease
has PubMed Central identifier	PMC7185428
has PubMed identifier	32363252
schema:publication	Curr Opin Syst Biol
resource representing a document's body	covid:c805511b956fda272fe0b6a09c9e000bc661bfaf#body_text
is schema:about of	named entity 'TRAITS' named entity 'tractable' named entity 'systems biology' named entity 'data' named entity 'population' named entity 'individual' named entity 'infectious disease' named entity 'VIEW' named entity 'SUB-' named entity 'SUSCEPTIBLE' named entity 'SYSTEMS BIOLOGY' named entity 'THERAPEUTIC' named entity 'PATHOPHYSIOLOGY' named entity 'TOLERANCE' named entity 'MARKEDLY' named entity 'PATIENTS' named entity 'SELECTION PRESSURE' named entity 'GROUPS' named entity 'HIGH' named entity 'BIOLOGY' named entity 'APPROACHES' named entity 'SYSTEMS MEDICINE' named entity 'SOLUTIONS' named entity '282' named entity 'MINIMAL' named entity 'TARGETS' named entity 'INFECTIOUS DISEASE' named entity 'ALMOST CERTAIN' named entity 'PREDICT' named entity 'CLINICAL' named entity 'SURVIVES' named entity 'REVEAL' named entity 'TARGETS' named entity 'PROBLEMS' named entity 'GENERATED' named entity 'MEDICINE' named entity 'ORGANISMS' named entity 'APPLICATIONS' named entity 'FORCE' named entity 'FEATURES' named entity 'THERAPEUTIC' named entity 'INFECTIOUS DISEASE' named entity 'SYSTEMS BIOLOGY' named entity 'POPULATION' named entity 'DEVELOPING' named entity 'HOST' named entity 'THERAPIES' named entity 'NEW' named entity 'COMPLEXITY' named entity 'ALTERING' named entity 'CONSEQUENCE OF' named entity 'PHENOTYPING' named entity 'COULD BE' named entity 'SHARE' named entity 'OBSERVED' named entity 'IMMUNE SYSTEM' named entity 'GOALS' named entity 'SUBGROUPS' named entity 'THROUGHPUT' named entity 'TARGETED' named entity 'IN VITRO' named entity 'ITS' named entity 'FRUSTRATED' named entity 'DISEASE' named entity 'GOALS' named entity 'REQUIRED' named entity 'INFECTION' named entity 'GREATLY' named entity 'RESPONSE' named entity 'AMENABLE' named entity 'TRAITS' named entity 'SUSCEPTIBILITY' named entity 'INDUCE' named entity 'MAJOR' named entity 'OLD' named entity 'ONE OF' named entity 'EXIST' named entity 'EVOLUTION' named entity 'TREATMENT' named entity 'ASPIRATION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software